Since the launch of Wegovy in pharmacies in France, the landscape of injectable treatments for obesity has transformed. The topic is no longer limited to comparing molecules: the question now concerns access conditions, actual indications, and the misuse related to off-label use. Distinguishing between what pertains to obesity treatment and what pertains to misuse has become essential.
Access to injections for weight loss: who can truly benefit
One of the least addressed angles in mainstream content concerns the medical selection of patients. Injections based on semaglutide or tirzepatide are not comfort products. They are reserved for profiles defined by BMI criteria and comorbidities.
See also : Work stoppage: everything you need to know about the rules and consequences for employees
Wegovy is indicated for adults and adolescents from 12 years old who have obesity or overweight, in conjunction with a low-calorie diet and increased physical activity. It is only used when lifestyle modifications and nutritional management have not been sufficient.
To better understand the different injections for weight loss, it is important to keep this strict filter in mind: the prescription is not intended for anyone wishing to lose a few pounds.
Read also : Everything You Need to Know About Using Bioderma Micellar Water for Radiant Skin
Semaglutide, tirzepatide, liraglutide: what really distinguishes these molecules
Grouping all injections under the label “weight loss injections” masks real pharmacological differences. The current market relies mainly on three molecules, each with a distinct mechanism and positioning.
Semaglutide: the most publicized molecule
Semaglutide is a GLP-1 analogue. It slows gastric emptying, increases the feeling of fullness, and decreases appetite. It is found in Wegovy (indicated for weight loss) and in Ozempic (indicated for type 2 diabetes). The distinction between these two specialties is fundamental, as their dosages and authorizations differ.
Tirzepatide: a dual mechanism
Tirzepatide, marketed under the name Mounjaro, acts on both GLP-1 and GIP receptors. This dual agonism distinguishes it from other injectable treatments. Available data suggest effectiveness in weight reduction, but field feedback still diverges on the long-term tolerance profile compared to semaglutide.
Liraglutide: the precursor
Liraglutide (Saxenda for weight loss, Victoza for diabetes) is a daily injection GLP-1 analogue, whereas semaglutide is administered once a week. This frequency constraint, combined with an effectiveness generally considered lower for weight loss, has repositioned liraglutide behind newer molecules.
Misuse: when antidiabetic medications become appetite suppressants
The most concerning phenomenon surrounding these treatments is their off-label use. Medications designed for type 2 diabetes are being misused for weight loss by individuals who do not meet the criteria for obesity or overweight with comorbidities.
Ozempic, initially prescribed to balance blood sugar in diabetic patients, has seen its demand explode for weight loss use. This misuse creates a double problem:
- Diabetic patients who need it face supply tensions, sometimes stock shortages in pharmacies.
- Individuals using these injections without appropriate medical supervision expose themselves to gastrointestinal side effects (nausea, vomiting, digestive disorders) without benefiting from nutritional support.
This phenomenon illustrates a gap between public perception (an injection that makes you lose weight) and medical reality (a treatment for obesity integrated into a care pathway).
Reimbursement and out-of-pocket costs: the economic filter for access to treatment
The financial question acts as a second filter after medical indication. The issue is no longer just about which injection works, but who can afford it. In France, coverage by health insurance depends on the regulatory framework specific to each specialty and the opinion of the HAS.
For Wegovy, a reevaluation opinion was pending at the time of its availability in pharmacies. This situation creates a zone of uncertainty for patients: a treatment available does not mean a treatment reimbursed. The out-of-pocket costs can represent a significant monthly expense, which effectively directs access towards more affluent socio-economic categories.
The available data do not yet allow for conclusions on the real impact of this financial barrier in terms of public health, but it raises a question of equity in access to care for obese patients.
Side effects of weight loss injections: what post-marketing surveillance reveals
The most frequently reported adverse effects with GLP-1 analogues are gastrointestinal: nausea, diarrhea, constipation, abdominal pain. These effects are often dose-dependent, which explains the gradual escalation protocols planned by manufacturers.
- Regular medical monitoring remains a condition of treatment, not an option.
- A treatment abruptly interrupted can lead to rapid weight regain, a point rarely highlighted in promotional content.
The long-term safety profile of these molecules, particularly tirzepatide, is still under active monitoring. The first years of wide commercialization will provide more solid data on rare or delayed risks.
Injections for weight loss are medications, not shortcuts. Their documented effectiveness does not exempt from verified medical indication, structured nutritional follow-up, or consideration of the real cost to the patient. Reducing these treatments to a promise of rapid weight loss ignores the framework in which they were designed.